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Currently, efforts have been directed towards using decavanadate as a tool for the understanding of
several biochemical processes such as muscle contraction, calcium homeostasis, in vivo changes of
oxidative stress markers, mitochondrial oxygen consumption, mitochondrial membrane depolarization,
actin polymerization and glucose uptake, among others. In addition, studies have been conducted in
order to make vanadium available and safe for clinical use, for instance with decavanadate compounds
that present interesting pharmacological properties, eventually useful for the treatment of diabetes.
Here, recent contributions of decavanadate to the effects of vanadium in biological systems, not only
in vitro, but also in vivo, are analysed
1. Introduction
Vanadium is a transition metal well known due to its toxicity
and accumulative behaviour at speciﬁc targets, such as bone, renal
and hepatic tissues. Although in simple organisms, vanadium is
considered to be essential, for instance for the functioning of
some enzymes, the essentiality of vanadium in higher animals
and human beings is still to be clariﬁed.1,2 Several studies correlate
vanadium-deﬁcient nutrition with retarded skeletal development,
bone deformities and impairment of fertility in goats, chickens
and rats.1 However, the role of vanadium in these processes is
not yet understood. Under physiological conditions vanadium
exists in several oxidation states, the +5 (vanadate) and +4
(vanadyl) being the most common. Intracellularly, the observed
reduction of vanadate to the blue vanadyl cation, may be
mediated by several small molecules such as glutathione (GSH),
ﬂavoenzymes, nicotinamide adenine dinucleotide, reduced form
(NADH), nicotinamide adenine dinucleotide phosphate, reduced
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form (NADPH) or noradrenaline, and by enzymes such as
NADH oxidases.3,4 Vanadate seems to be more toxic for living
systems, and its conversion to vanadyl has been proposed as a
detoxiﬁcation mechanism.5,6 Vanadium and vanadium complexes,
have been shown to inhibit and stimulate several enzyme activities,
such as ATPases, phosphatases, kinases, nucleases and other
enzymes, besides being found to be present at the active centre of
haloperoxidases and nitrogenases and to bind to speciﬁc proteins
such as vanabins.7–11
The interest in vanadium increased among biochemists and
cell biologists since Josephson and Cantley identiﬁed vanadate
as an impurity in commercial ATP prepared from equine muscle,
a potent inhibitor of the sodium/potassium pump.12 Although
thirty years have passed since the discovery of this speciﬁc P-type
ATPase inhibitor, the major role of this element in biology is still
unidentiﬁed. More recently, at least four compendia on different
aspects of vanadium have appeared covering chemistry, biochem-
istry, biology, pharmacology and medicine;13–16 a testimony to
the interest in this element. Presently, the medicinal applications
of vanadium are progressing through various studies: structure–
activity relationships of antidiabetic vanadium complexes; using
vanadium compounds as anti-tumour drugs and anti-parasitic
agents; improving bioactive ligand activity through complexation
with vanadium; investigating the osteogenic action of vanadium
compounds and their cytotoxicity, in order to make vanadium
available and safe for clinical use.15 Milestones in the history
of vanadium biochemistry are the studies on the redox proﬁle
of vanadium, the role of vanadium in bromoperoxidases, the
vanadium binding proteins in ascidians and, more recently, deca-
vanadate interactions with lipidic structures, muscle proteins and
the in vivo effects induced by the decameric vanadate species.15,17
Currently, decavanadate, a vanadate oligomer, is well known to
exhibit many biological functions. A review of biological activities
of decavanadate is given in a recent paper.17 One of these studies
points to mitochondria as a potential target for decameric toxicity,
and also associates the effects of decavanadate with bioenergetics
processes.15,17 Therefore, otherwise neglected, decavanadate has
travelled a journey in a search of a role, but along the way it
has been found to be a very useful tool in the understanding of
protein structure and function, biochemical mechanisms and a
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range of biological processes such as muscle contraction, calcium
homeostasis, necrosis, extra cellularmineralization,mitochondrial
oxygen consumption, in vivo oxidative stress markers, glucose
uptake and actin polymerization, among others (Fig. 1).
Fig. 1 Examples of biological processes affected by decavanadate, in vivo;
oxidative stress markers, lipid peroxidation and in vitro; necrosis, calcium
homeostasis, muscle contraction, actin polymerization, mitochondrial
oxygen consumption and mitochondrial membrane depolarization.
However, many researchers do not think that the role of
decavanadate canbeof signiﬁcance.That is themain reasonwhy, in
my opinion, this perspective is important, because people really do
not currently believe that decavanadate might have an important
biological role, in part because decavanadate alone might not
exist or never exists in solution for a long time. However, the
facts are, for example, data showing that 1 mM of decavanadate
strongly affects mitochondria, that it is stabilized by proteins and
that administrating decavanadate in vivo induces different effects
to monomeric vanadate in lipid peroxidation and antioxidant
stress markers. In my opinion, contradictory biological results
are achieved because researchers are using solutions containing
decameric vanadate species, which are responsible for many of
the observed effects. This is because it is very easy to obtain a
pale yellow colour (meaning the presence of decavanadate) in
the vanadate solutions that we are using. Putting it all together,
this article is intended to provide more questions than answers
regarding the role of decavanadate in biological systems; a ﬁeld
that is certainly open to further and exciting research.
1.1 The complex chemistry of vanadium, an element with many
biological functions
It is not surprising that the role of vanadium in biological
systems has a long and controversial history, if one consider
the exceptionally complex chemistry of vanadium in solution,
especially concerning the possibility of several oxidations states,
the propensity of vanadate species to condense, forming vanadate
oligomers, at higher concentrations or acidic pHs, or to interact
with countless compounds of biological interest.3,7,10,15,17 Over the
last 20 years, many studies have been conducted to learn more
about the contribution of oligomeric vanadate species, particularly
decameric vanadate, to the effects induced by vanadate.10,15,17,25 It
was demonstrated that decavanadate can have different effects
to the monomeric vanadate form in biological systems, not only
in vitro but also in vivo.15,17 Furthermore, it is considered to be of
extreme importance to have well-characterized compositions of
the vanadium and vanadium complex solutions in these studied
conditions, in order to correctly identify which vanadium species
are promoting the observed effects.10,15,17,20–22 Usually, this can be
achieved combining kinetic with spectroscopic studies.10,15,17
Numerous researchers using vanadate in their studies, working
in different areas ranging from life sciences to chemical engi-
neering, have to deal with the tendency of vanadate species to
oligomerize. At neutral pH, and through the range of concen-
trations most frequently employed in biochemical and biological
studies (mM), the predominant vanadate species are the monomer
(H2VO4-), dimer (H3V2O7-), tetramer (V4O124-)15,17,23,24 and de-
camer, also known as decavanadate, with the formula V10O286-.
The decavanadate anion has ten V ions with each ion surrounded
by six oxygen atoms (Fig. 2). There are three types of vanadium
ion, which can be distinguished by 51V NMR spectroscopy, as
described elsewhere.15,17
Fig. 2 The schematic structure of V10 (V10O286-).
The relative concentration of these species is a function,
for example, of pH and vanadium concentration, among other
experimental conditions.10,15,17 Given the rapid exchange rates
between the labile oligovanadates, it is not possible to isolate a
speciﬁc anion and, consequently, an equilibrium mixture must be
examined25, which may complicate studies aimed to determine
the biological effect of a speciﬁc anion.10,15,17 Therefore, at the
concentrations normally used in biological studies (mM) the
vanadate solutions will also contain several vanadate oligomers
and not only monomeric vanadate. However, in most biological
studies, these vanadate oligomers are often not taken into account,
although it is recognized that the individual species may inﬂuence
enzyme activities differently.15,17,20–22,24–41,46
Among the vanadate oligomers, decavanadate is the one with
higher biological impact. To my knowledge, it is not possible to
prevent the formation of decameric vanadate upon acidiﬁcation
of vanadate solutions. If acidiﬁcation occurs after the preparation
of a vanadate solution (10 mM), it is possible to immediately
observe the appearance of a yellow colour due to the occurrence
of decameric vanadate species, even if the global pH value of
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the solution does not change signiﬁcantly (Fig. 3). In fact, many
researchers using vanadate in their studies frequently observed
the orange/yellow color in their solutions due to the presence
of decameric vanadate: in a cell culture, after an acidiﬁcation
procedure during protein puriﬁcation, after the adjustment of the
pH value of the reaction medium or even in methods for vanadate
quantiﬁcation.
Fig. 3 Photography of two vanadate solutions, at ambient temperature,
obtained from a 10 mM metavanadate solution, pH 6.8, before (left) and
after addition of HCl (ﬁnal pH of 6.6 (right)). Decavanadate solutions
correspond to the latter situation, after the pH value is ascertained, to a
ﬁnal pH of 4.0. Vanadate solutions were prepared from solid NH4VO3.
The addition of conc. HCl induces the formation of decameric vanadate
species responsible for the yellow colour of the solution (adapted from
ref. 15).
Once formed, or when we prepare a solution of decavanadate,
the rate of decavanadate decomposition is slow enough (half-
life time of hours at 25 ◦C) to allow the study of its effects,
not only in vitro7,15,17,18,19,20,27,30,34,46, but also in vivo15,17,21,35,36,37,38,39,
as will be discussed below. Therefore, it is believed that, due to
its stability at certain physiological conditions, decavanadate will
not completely disintegrate into other vanadate oligomers before
inducing changes in vivo in several oxidative stress markers, lipid
peroxidation and in the activity of enzymes. As is described below,
these changes are different from the ones observed for vanadate
alone. In addition, it was recently observed that decameric
vanadate can be stabilized upon interaction with cytoskeleton and
membrane proteins27,40: the half-life time increases in the presence
of actin, in experimental conditions where protein polymerization
is occurring and in the presence of sarcoplasmic reticulum vesicles
(SRV) containing calcium ATPase (Fig. 4).
1.2 Decavanadate: a vanadate with many biological functions
The pioneering studies on the interaction between decavanadate
and proteins were performed with ribonucleases, in 1973.41
This, and other studies, demonstrated that the decavanadate
species was potentially responsible for the effects promoted by
vanadium in enzyme activities.7,15,17,34,40,46 Besides having high
potency in a number of systems, the lower lability of this
large polyoxoanion allows it to be used as an excellent kinetic
and spectroscopic probe.15,17,20,27,33,34,40,46 For instance, in skeletal
muscle proteins, many studies have been done to learn more
about the contribution of the different oligomeric vanadate
species, particularly decavanadate and vanadium complexes, to
the effects of vanadium on muscle contraction/relaxation, namely
on the sarcoplasmic reticulum (SR) Ca2+-ATPase transmembrane
transport system15,17,22,40 and on molecular motor (myosin and
actomyosin) ATPase activities.15,17,27,33,34,40 These studies proposed
that decavanadate inhibits actomyosin ATPase and SR ATPase
activity by a different mechanism than the one described for
monomeric vanadate. For example, the studies of the interaction
Fig. 4 Decavanadate stabilization by actin and calcium pump. Decavanadate (10 mM V10 species or 100 mM total vanadium) half-life time in presence
of: () G-actin in polymerization buffer (Tris 2 mM, CaCl2 0.2 mM, ATP 10 mM, KCl 100 mM, MgCl2 2 mM, pH 7.5); () G-actin in non-polymerization
buffer (Tris 2 mM, CaCl2 0.2 mM, ATP 0.2 mM, pH 7.5); (H17009) F-actin (in Tris 2 mM, CaCl2 0.2 mM, ATP 10 mM, KCl 100 mM, MgCl2 2 mM, pH 7.5);
() myosin (in Tris 2 mM, CaCl2 0.2 mM, ATP 0.2 mM, pH 7.5); () SRV (in KCl 0.1 M, MgCl2 5 mM, HEPES 25 mM, CaCl2 50 mM, ATP 500 mM,
pH 7.0); (★) liposomes (POPC multilamellar vesicles in Tris 2 mM, pH 7.5). Half-life times were determined from the slopes of the linear least-squares
ﬁt of (right graphic) the ln Abs 400 nm as a function of time. (Adapted from ref. 27.)
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of decameric vanadate with myosin and actin are an example of
the contribution of vanadate oligomers to the effects of vanadate
in myosin structure and function. In fact, although the mechanism
of inhibition of the monomeric species towards myosin has been
relativelywell characterized, very little has been reported about the
contribution of vanadate oligomers to the biochemical/structural
properties of myosin. In the ﬁrst place, a considerable difference in
the ability of vanadate to inhibit the myosin and the actomyosin
ATPase activities was found. While in the absence of actin,
vanadate inhibits myosin ATPase activity in the submicromolar
concentration range, but in the presence of actin, much higher
concentrations (> 900 mM) are needed.42 The need for such high
concentrations strongly suggested that this effect could be due to
oligomeric vanadate species that are favoured at higher vanadate
concentrations and which are likely to operate through a different
mechanism. This hypothesis was further investigated, starting
by clarifying which vanadate oligomers interact more potently
with myosin and how this interaction modulated myosin–actin
interactions.
Kinetic studies showed that, unlike vanadate, the decameric
species is able to strongly inhibit the myosin or myosin
subfragment-1 (S1) actin-stimulated ATPase activity with an IC50
in the micromolar range. These results demonstrated the initial
hypothesis that the inhibition of the actin-stimulated myosin
ATPase activity by millimolar vanadate concentrations is, in
reality, due to thepresenceof decavanadate andnot themonomeric
vanadate species (Fig. 5). A detailed kinetic analysis revealed
that decavanadate inhibition is non-competitive regarding ATP,
yielding an inhibition constant (K i = 0.27 ± 0.05 mM)34 that is in
the range of K i values previously reported for enzymes inhibited
by decavanadate.7
Fig. 5 Inhibition of the actin-stimulated ATPase activity of myosin
() or myosin subfragment-1 () by vanadate (given as total vanadium
concentration). In the presence of actin, decameric vanadate, unlike the
monomer, is able to inhibit myosin ATPase activity in the micromolar
range. The assays were performed using a coupled enzyme system with
50 mg ml-1 enzyme and 5 mM F-actin, at 25 ◦C, in a medium containing
10 mM Tris-HCl, pH 7.0, 2.5 mM MgCl2 and 2 mM ATP. The lines are
the nonlinear least squares ﬁt of the data to a Michaelis–Menten-like
equation with the following parameter values: Imax = 100 and IC50 =
6.11 ±0.74 mM V10 (or 61.1 ±7.4 mM total vanadium) and IC50 = 1.36
±0.14 mM V10 for myosin and S1, respectively [34]. (With permission from
Research Signpost Editors, Kerala, India [ref. 15].)
It has been shown that the walker A motif (corresponding to the
P-loop in myosin) of ABC ATPases is an anion-binding domain
that can bind decavanadate with high afﬁnity.43 Unlike vanadate,
decavanadate appears to interact outside the walker A loop but
needs to be stabilized by certain residues nearby. As a result, only
some members of the ABC ATPases are able to interact with the
decameric vanadate species. With respect to myosin, the speciﬁc
phosphate-binding domains in the vicinity of the nominated
“back-door” binding site provide electrostatic interactions which
favour an approach of decavanadate, as analysed using docking
studies33 (Fig. 6). Once “docked” to the 50 kDa cleft and stabilized
by certain residues nearby33, the large size of decavanadate is likely
to interfere with movements associated with closure of the cleft,
a critical conformational change necessary to carry out the ATP-
g-phosphate hydrolysis during the process of the ATP hydrolysis
by the actin–myosin complex.34 Therefore, by forming the inter-
mediate myosin–MgATP–decavanadate complex, decavanadate
will act as a “back-door” inhibitor blocking the actomyosin
cycle during the process of ATP hydrolysis, most likely in the
pre-hydrolysis state. In conclusion, while monomeric vanadate
mimics the transition state for the g-phosphate hydrolysis blocking
myosin in a pre-power-stroke state, decameric vanadate induces
the formation of the intermediate myosin–MgATP–V10 complex,
blocking the contractile cycle presumably in the pre-hydrolysis
state. Furthermore, while the former complex is destabilized in the
presence of actin, comparable to the in vivo conditions, the latter
is not.34
Fig. 6 Structures of S1 and decavanadate, and suggested location of the
high afﬁnity binding site for decavanadate. The location of the active site
with respect to the decavanadate molecule is shown. Positive, neutral and
negative surface potentials are coloured in red, white and blue, respectively.
The decavanadate molecule is adjusted to the 50 kDa cleft at the back of
the nucleotide site.
Contrary to myosin, not much information is available at
molecular level about the interaction of decavanadate with actin,
the othermajor protein of the contractile systemof themuscle cells.
As described above, it was suggested that the actin interactionwith
decavanadate, stabilizes, at certain experimental conditions, the
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decomposition of decavanadate (Fig 4). Moreover, it was reported
that decavanadate prevents F-actin polymerization, therefore
affecting cytoskeleton structures responsible, among others things,
for the shape of the cells.27 On the other hand, in our Cellular and
Inorganic Biochemistry research group, it was recently observed
that the interactionof decavanadatewith actinmay induce cysteine
oxidation and vanadate reduction.44 In this study, it has not been
determined which vanadate undergoes reduction, but it is possible
that V10 could be more prone to reduction than the metavanadates,
as described elsewhere.17,45 Furthermore, the ability of V10 to
undergo redox chemistry was conﬁrmed in studies subjecting
decavanadate to photoreduction4 and protein photocleavage46 and
maybe, at least in part, amode of action in biological systems.17,46,47
In addition to pumps, channels and metabotropic receptors,
molecular motors represent potential biological targets for deca-
vanadate and some examples have been reported.15,27–33 In con-
clusion, decavanadate interacts with enzymes at polyphosphate,
nucleotide and inositol 3-phosphate binding sites in the substrate
domain or in an allosteric site, in a complex manner.15,17,27–33
1.3 Effects of decavanadate upon in vivo administration
Very few in vivo animal studies involving vanadium consider
the contribution of decavanadate (V10) to vanadium biological
effects.15,17,21,35–39 These in vivo studies, suggest that decameric
vanadate may not completely fall apart into other vanadate
oligomers before inducing changes in cell homeostasis, namely
in several oxidative stress markers, among other biological pa-
rameters. It was demonstrated that an acute exposure of differ-
ent ﬁsh species (Halobactrachus didactilus, Lusitanian toadﬁsh;
Sparus aurata, gilthead seabream) to decavanadate, but not
other vanadate oligomers, induced different effects than vanadate
exposure, namely in catalase activity, glutathione content, lipid
peroxidation, mitochondrial superoxide anion production and
vanadium accumulation, whereas both solutions seem to depress
reactive oxygen species (ROS) production equally, as well as the
total intracellular reducing power.15,17,21,35–39 Moreover, exposure
to different vanadate oligomers induced morphological changes
in ﬁsh cardiac, hepatic and renal tissues causing tissues lesions in
the liver and kidney, but not in cardiac tissue. Nevertheless, the
results highlight that different vanadate oligomers seem to follow
different pathways, not only in vitro but also in vivo, with different
targets and effects. These recent ﬁndings, summarized here, point
out the importance of taking into account the contribution of
decameric vanadate species to in vivo effects induced by vanadium
in biological systems.
Since 1999, in vivo administration of decavanadate has been
performed in order to understand the contribution of decameric
vanadate species to the toxic effects of vanadate.35–40 Among the
different experimental conditions were (i) the mode of decavana-
date administration (intraperitoneal, i.p. versus intravenous, i.v.);
(ii) ﬁsh species (Halobatrachus didactylus—Lusitanian toadﬁsh—
and Sparus aurata—gilthead seabream); (iii) vanadate concentra-
tion (1 and 5 mM); (iv) tissues (cardiac, hepatic, renal, blood);
(v) subcellular fractions (cytosol, mitochondria, red blood cells,
blood plasma); and (vi) exposure time (1, 6, 12, 24 h; 2 and 7
d). A metavanadate solution, not containing decameric vanadate
species, was always administered as a comparison study group
and, up to now, following in vivo administration of decavanadate,
several parameters have been analysed, such as (i) vanadium
subcellular distribution35,37,39; (ii) histological changes on cardiac,
hepatic and renal tissues38; (iii) effects on sarcoplasmic reticulum
Ca2+-pump15; (iv) lipid peroxidation; and (v) antioxidant enzymes
activities besides several oxidative stress markers in heart35,37,40
and liver.39,40 These reports indicated a different in vivo metabolic
pattern for decameric vanadate species, with different vanadate
species inducing different effects on vanadium subcellular distri-
bution, tissue damage in liver, kidney and heart, lipid peroxidation
and antioxidant enzymes17,35–40, pointing out the importance of
characterizing vanadate solutions in evaluating vanadium toxicity
in biology.
Therefore, it was clearly demonstrated that upon decavanadate
administration, or when it is formed in physiological conditions, it
may live for long enough to induce different biological effects
than the ones observed for vanadate alone. However, in vivo
toxicological studies of these species are scarce and the role of
decameric vanadate in biological systems is still to be clariﬁed.
Several biological studies associate vanadium with the ability to
produce reactive oxygen species (ROS), resulting in lipid peroxi-
dation and antioxidant enzyme alterations, leading to oxidative
stress.48–53 In agreement with the increase in ROS production
previously reported, 1 mM metavanadate induces an increase
(+115%) in mitochondrial superoxide dismutase (SOD) activity
(p <0.05), 12 h after exposure, while decavanadate increases it by
about 30% (p <0.05) (at 1 and 12 hours after intravenous, i.v.,
administration).37 It is known that SOD activity may increase
with the need to protection against oxidizing agents, such as
vanadate. Apparently, only metavanadate species act as a pro-
oxidant since decavanadate does not induce the same overall
response, probably due to different reactivities that can result
from different mechanisms. Concerning mitochondrial catalase
(CAT) activity, the basal CAT activity in mitochondria (1.63 ±
0.51 nmol min-1 mg-1 protein) decrease by -55% (p <0.05)
12 h after decavanadate exposure, whereas metavanadate induced
no signiﬁcant effects.37 Altogether, 1 mM decavanadate in vivo
administration differs from metavanadate in not inducing car-
diac mitochondrial ROS production and SOD activity, besides
decreasingCATactivity. Therefore,more pronounced pro-oxidant
effects occur in cardiac mitochondria following i.v. metavanadate
exposure whereas decavanadate administration seems to prevent
this effect, probably by binding to target proteins that prevent its
decomposition to vanadate that induces the production ofROS, or
due to different reactivities. In conclusion, upon administration,
the decameric vanadate species has a different reactivity than
vanadate, once again making it clear that different contributions
of vanadiumoligomers should be taken into account to rationalize
in vivo vanadate toxicity.
One thing is becoming clear, decavanadate seems to follow
different pathways, not only in vitro but also in vivo, with
different targets and effects than other vanadate oligomers. It
is well known that, in the cell, vanadate or even decavanadate
is reduced to vanadyl, preventing the toxic effects of vanadium.
However, decavanadate impacts speciﬁc targets, for example
mitochondria15,17,20,30, thus inducing different cellular responses
than other vanadate species (Fig. 7). Decameric species may even-
tually occur upon intracellular acidiﬁcation, becoming accessible
to speciﬁc protein binding sites and inaccessible to reduction,
thus inducing different cellular responses than the other vanadate
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Fig. 7 Scheme of the proposed cellular targets of decavanadate (V10): V10
uptake through anionic channels (AC) and/or V10 binding to membrane
proteins, as well as V10 formation upon intracellular acidiﬁcation; reduc-
tion of monomeric vanadate (V1) by antioxidant agents and the reduction
of V10 by enzymes, as well as the binding of V10 to target proteins;
and ﬁnally, the accumulation of V10 into subcellular organelles, such as
mitochondria, suggests that these are a target for decavanadate (adapted
from Aureliano and Gaˆndara [ref. 40]). (With permission from Research
Signpost Editors, Kerala, India [ref. 15].)
species. It was also observed that vanadium accumulates in
Sparus aurata mitochondria, in particular, when decavanadate is
administrated.15,17 As described below, several studies point out
mitochondria as one of the potential targets for decavanadate.
1.4. Mitochondria: a target for decavanadate
A compound that inhibits mitochondrial oxidative phospho-
rylation can have a profound effect on the metabolism of
important organs like the heart, kidney, liver and brain. As
described above, vanadium tends to accumulate more after the
administration of decavanadate solution36,37 than upon vanadate
exposure. Moreover, in vivo decavanadate administration points
to speciﬁc effects in mitochondrial activity,30 besides affecting
mitochondrial antioxidant enzyme activities.35,37,39 These results
suggested that decavanadate is not behaving in the same way
as other vanadate oligomers and indicated that, apparently, the
mitochondria seem to be a target for decavanadate (Fig. 7). All
the above data support the hypothesis that mitochondria might be
a target for decameric vanadate species. This hypothesis has been
further explored and recent evidence20,30 reports that decameric
vanadate inhibits mitochondrial respiration and induces mito-
chondrial membrane depolarization in vitro to a larger extent than
metavanadate, in both rat liver and ﬁsh heart mitochondria.20,30
For instance, decavanadate concentrations as low as 0.5 mM,
inhibit oxygen consumption in intact cardiac mitochondria by
about 50%, while a 50-fold higher concentration of metavanadate
(25 mM) is needed to induce the same effect (Fig. 8A) pointing
out mitochondria as a potential cellular target for decavanadate
toxicity.30 Moreover, decameric vanadate also induced cardiac
mitochondrial depolarization (IC50 = 0.5 mM) more strongly than
metavanadate (IC50 = 50 mM) (Fig. 8B).30
Decavanadate inhibits bothmitochondrial oxygen consumption
and membrane potential more strongly than vanadate, acting
as a potent inhibitor probably by affecting complex III of the
respiratory chain of the mitochondrial inner membrane.15,17
1.5 The role of vanadium versus pharmacological and medicinal
effects
Several biological studies associate the mode of action of vana-
dium through the regulation of the level of tyrosine protein
phosphorylation54,55 or through oxidative stress.56,57 In the last
case, the ability to produce reactive oxygen species (ROS), results
in lipid peroxidation and antioxidant enzyme alterations, leading
to oxidative stress.17,30–53 The formation of reactive oxygen species
(ROS) induced by vanadium in biological systems may involve
Fenton-like reactions48, vanadate bioreduction mediated by re-
duced glutathione (GSH), ﬂavoenzymes or nicotinamide adenine
dinucleotide, reduced form (NADH), and nicotinamide adenine
dinucleotide phosphate, reduced form (NADPH), oxidases49,50
or interaction with mitochondria.20,30 Mitochondria, a potential
producer of ROS, have recently been suggested as a poten-
tial target of vanadium, decavanadate or monomeric vanadate,
since mitochondrial membrane depolarization is a key event
Fig. 8 Effects of decavanadate in mitochondria. Decavanadate () and metavanadate () in vitro inhibitory effects (up to 25 mM total vanadium) on ﬁsh
heart mitochondrial (2 mg protein ml-1) oxygen consumption (%), measured with an oxygen electrode (A); and mitochondrial membrane depolarization
(%) by decavanadate (H17009) and metavanadate () on ﬁsh cardiac mitochondria (15 mg protein ml-1), at 25 ◦C, in the presence of 5 mM GSH (B); mean ±
STD (adapted from Soares et al. [ref. 30]). (With permission from Research Signpost Editors, Kerala, India [ref. 15].)
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in vanadate-induced necrotic cell death of cardiomyocytes.20
Moreover, efforts have been dedicated in recent years to learn
more about the characterization of effects in bone-derived systems
by vanadium, namely signalling pathways, extracellular matrix
inhibition and inhibition of alakaline phosphatase activity, that
impact cell differentiation.18,19 Also, the short- and long-term ef-
fects of metavanadate (containing monomeric, dimeric, tetrameric
and pentameric vanadate species) and decavanadate (containing
decameric vanadate species) solutions on the mineralization of
a ﬁsh bone-derived cell line (VSa13) associated with the chon-
drocyte lineage were studied and compared to that of insulin.
After 2 h of incubation with vanadate (10 mM in monomeric
vanadate),metavanadate exhibited higher accumulation rates than
decavanadate (6.85 ± 0.40 versus 3.95 ± 0.10 mg V per g of protein,
respectively) in ﬁsh VSa13 cells and was also shown to be less toxic
when applied for short periods. In longer treatments with both
metavanadate and decavanadate solutions, similar effects were
promoted: stimulation of cell proliferation and strong impairment
(75%) of extracellular matrix (ECM) mineralization. The effect of
both vanadate solutions (5 mM in monomeric vanadate), on ECM
mineralization was increased in the presence of insulin (10 nM).18
Since it displays insulin-like activity through correction of
metabolic disorders associated with insulin deﬁciency, it has been
suggested that vanadium and vanadium compounds could be used
in diabetes treatments.58 Applications of vanadium compounds for
the treatment and prevention of type 2 diabetes mellitus (T2DM)
have been ongoing for more than two decades.59 Several vanadium
compounds have been reported to lower glycaemia and normalize
plasma lipid proﬁles in animal models of diabetes. So far,
vanadium(IV) complexes or vanadyl complexes, have been used in
clinical trials.58,59 Despite these and other studies, the mechanisms
underlying the activation of glucose uptake by vanadium are
still to be clariﬁed.58–61 Glucose uptake in adypocytes has also
been reported to be affected by insulin-mimetic compounds such
as decavanadate compounds that act independently of insulin62,
therefore increasing the interest of inorganic chemists in the
synthesis of these types of compounds. Recently, in our research
group, it was demonstrated that decavanadate (25 mM) alone also
stimulated glucose uptake in primary rat adipocytes, and partially
reverts the insulin-resistance effect induced by glucocorticoids
such as dexamethasone (Pereira et al., unpublished results),
therefore revealing an interesting pharmacological action.63
1.6 Concluding remarks and future perspectives
In the last decade, considerable effort has been made in studying
the function of decavanadate in biological systems as well as its
role in catalytic and pharmaceutical applications. These studies
point to the importance of taking into account decavanadate,
which, once formed, may not completely fall apart, in the
evaluation of vanadium biological effects. In addition to its
biological functions in living organisms, decavanadate is a very
interesting oligovanadate in therapeutical applications, particu-
larly because many decavanadate complexes present interesting
pharmacological properties and also showed antidiabetic effects.
The mechanisms involved in the pharmacological mode of actions
of vanadium are under research. In fact, the knowledge of
the vital functions displayed by different vanadium compounds
attracted the interest of researchers to vanadium coordination
compounds with potential therapeutic applications. Therefore,
various vanadium and decavanadate ions–organic ligand com-
plexes were synthesised to obtain more potent medicines than
inorganic vanadium salts. For this reason, it is very interesting to
study the effects of decavanadate and vanadium compounds in
biological systems.
Whether decavanadate can exist and possibly even form under
physiological conditions is a question yet to be answered. But
can decameric vanadate be stable enough to induce physiological
effects? The answer is yes, depending on the mode of administra-
tion, concentration and time of exposure. Having established that
decavanadate can form and exist inside a cell, the question then
becomes whether it speciﬁcally affects some cellular processes?
The answer to this question is also yes, with examples including
oxidative stress markers to mitochondrial depolarization. There-
fore, research into vanadium toxicology and pharmacology should
also involve decavanadate.
Perspectives of the research with decavanadate that remain to
be addressed include the following questions: (i) is it possible
to prevent the formation of decavanadate? (ii) Once formed,
can the disintegration of decavanadate be prevented? (iii) Can
decavanadate be formed in mitochondria? (iv) What is the role
of decavanadate in the in vivo regulation of myosin and other
molecular motors? (v) What is the molecular mechanism of
interaction between actin and decavanadate? (vi) Does decavana-
date enter into cells or does it operate through the membrane?
(vii) Are the in vivo effects induced by decavanadate due to
interactions with membrane proteins or with the membrane?
(viii) Does decavanadate induce in vivo effects due to speciﬁc
cytoplasmatic protein targets? (ix) What about the interaction of
decavanadate with nucleotides and molecules related to DNA? (x)
Is the reduction of decavanadate upon interaction with proteins
one of the processes of action in biological systems? (xi) Can it
be described at a molecular level the interactions of decavanadate
and decavanadate compounds with the target proteins?
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